NCT03923478View on ClinicalTrials.gov

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions
Ulcerative Colitis Chronic MildUlcerative Colitis Chronic Moderate
Interventions
DRUG

ABI-M201

Active Treatment

DRUG

Placebo

Control Treatment

Trial Locations (11)

30033

(Investigator Site), Decatur

38305

(Investigator Site), Jackson

48047

(Investigator Site), Chesterfield

48197

(Investigator Site), Ypsilanti

53226

(Investigator Site), Milwaukee

55905

(Investigator Site), Rochester

71105

(Investigator Site), Shreveport

94070

(Investigator Site), San Carlos

94612

(Investigator site), Oakland

98004

(Investigator Site), Bellevue

P3C 5K6

(Investigator site), Greater Sudbury

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT03923478 - ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter